{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:39:19Z","timestamp":1767857959309,"version":"3.49.0"},"reference-count":17,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2018,9,25]]},"DOI":"10.1253\/circj.cj-17-1424","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T22:33:54Z","timestamp":1532558034000},"page":"2575-2583","source":"Crossref","is-referenced-by-count":19,"title":["Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction\u3000\u2015 Baseline Characteristics and Treatment of PARALLEL-HF Trial \u2015"],"prefix":"10.1253","volume":"82","author":[{"given":"Hiroyuki","family":"Tsutsui","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Momomura","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Jichi Medical University, Saitama Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Nara Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, Tottori University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Okino","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihito","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weinong","family":"Guo","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kitakaze M. Trends in characteristics of CVD in Asia and Japan: The importance of epidemiological studies and beyond. <i>J Am Coll Cardiol<\/i> 2015; 66: 196\u2013198.","DOI":"10.1016\/j.jacc.2015.05.035"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. <i>Eur J Heart Fail<\/i> 2015; 17: 884\u2013892.","DOI":"10.1002\/ejhf.319"},{"key":"3","unstructured":"3. World Health Organization. The global burden of disease: 2004 update. Geneva: WHO, 2008."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med<\/i> 2014; 371: 993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation<\/i> 2015; 131: 54\u201361.","DOI":"10.1161\/CIRCULATIONAHA.114.013748"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: A network meta-analysis. <i>Circ Heart Fail<\/i> 2017; 10: e003529.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, et al. Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. <i>J Cardiol<\/i> 2017; 70: 225\u2013231.","DOI":"10.1016\/j.jjcc.2016.11.011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rajadurai J, Tse HF, Wang CH, Yang NI, Zhou J, Sim D. Understanding the epidemiology of heart failure to improve management practices: An Asia-Pacific perspective. <i>J Card Fail<\/i> 2017; 23: 327\u2013339.","DOI":"10.1016\/j.cardfail.2017.01.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <i>Eur J Heart Fail<\/i> 2014; 16: 817\u2013825.","DOI":"10.1002\/ejhf.115"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, et al. Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). <i>Circ J<\/i> 2017; 82: 148\u2013158.","DOI":"10.1253\/circj.CJ-17-0323"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsutsui H, Momomura S, Yamashina A, Ogawa H, Shimokawa H, Kihara Y, et al. Heart rate control with I<sub>f<\/sub> inhibitor, ivabradine, in Japanese patients with chronic heart failure: A randomized, double-blind, placebo-controlled phase II study. <i>Circ J<\/i> 2016; 80: 668\u2013676.","DOI":"10.1253\/circj.CJ-15-1112"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction: A report from the CHART-2 Study. <i>Eur J Heart Fail<\/i> 2017; 19: 1258\u20131269.","DOI":"10.1002\/ejhf.807"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). <i>Circ J<\/i> 2009; 73: 1893\u20131900.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. <i>Eur Heart J<\/i> 2013; 34: 1404\u20131413.","DOI":"10.1093\/eurheartj\/ehs337"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: Insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>Eur Heart J<\/i> 2013; 34: 2823\u20132829.","DOI":"10.1093\/eurheartj\/eht247"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kristensen SL, Martinez F, Jhund PS, Arango JL, Belohlavek J, Boytsov S, et al. Geographic variations in the PARADIGM-HF heart failure trial. <i>Eur Heart J<\/i> 2016; 37: 3167\u20133174.","DOI":"10.1093\/eurheartj\/ehw226"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, et al. Initiating sacubitril\/valsartan (LCZ696) in heart failure: Results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>Eur J Heart Fail<\/i> 2016; 18: 1193\u20131202.","DOI":"10.1002\/ejhf.548"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/10\/82_CJ-17-1424\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T08:24:36Z","timestamp":1571646276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/10\/82_CJ-17-1424\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-17-1424","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]}}}